Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Rog

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
BMJ Open|November 26, 2021
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosisRuth Dobson, Matthew Craner, Ed Waddingham, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 3, 2021
Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS RegisterAfagh Garjani, Rachael Hunter, Graham R Law, et al.
Journal of the Neurological Sciences|March 18, 2022
The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implicationsCarolyn A Young, Roger Mills, Dawn Langdon, et al.
Multiple Sclerosis and Related Disorders|January 21, 2021
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 yearsAnn D Bass, Rafael Arroyo, Aaron L Boster, et al.
Multiple Sclerosis and Related Disorders|June 5, 2020
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 yearsJiwon Oh, Anat Achiron, Elisabeth G Celius, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 29, 2020
Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS RegisterNikos Evangelou, Afagh Garjani, Roshan dasNair, et al.
Brain : a Journal of Neurology|October 8, 2021
The impact of smoking cessation on multiple sclerosis disease progressionJeff Rodgers, Tim Friede, Frederick W Vonberg, et al.
Multiple Sclerosis and Related Disorders|May 31, 2022
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)Ruth Dobson, Matthew Craner, Ed Waddingham, et al.
The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.
BMJ Open|May 17, 2023
ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UKBenjamin M Jacobs, Luisa Schalk, Angie Dunne, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
BMJ Open|November 26, 2021
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosisRuth Dobson, Matthew Craner, Ed Waddingham, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 3, 2021
Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS RegisterAfagh Garjani, Rachael Hunter, Graham R Law, et al.
Journal of the Neurological Sciences|March 18, 2022
The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implicationsCarolyn A Young, Roger Mills, Dawn Langdon, et al.
Multiple Sclerosis and Related Disorders|January 21, 2021
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 yearsAnn D Bass, Rafael Arroyo, Aaron L Boster, et al.
Multiple Sclerosis and Related Disorders|June 5, 2020
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 yearsJiwon Oh, Anat Achiron, Elisabeth G Celius, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 29, 2020
Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS RegisterNikos Evangelou, Afagh Garjani, Roshan dasNair, et al.
Brain : a Journal of Neurology|October 8, 2021
The impact of smoking cessation on multiple sclerosis disease progressionJeff Rodgers, Tim Friede, Frederick W Vonberg, et al.
Multiple Sclerosis and Related Disorders|May 31, 2022
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)Ruth Dobson, Matthew Craner, Ed Waddingham, et al.
The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.
BMJ Open|May 17, 2023
ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UKBenjamin M Jacobs, Luisa Schalk, Angie Dunne, et al.
Pageof 5